Cidara Therapeutics

San Diego, United States Founded: 2013 • Age: 13 yrs Listed Acquired By Merck
Novel anti-infectives for bacterial and fungal infections are developed.

About Cidara Therapeutics

Cidara Therapeutics is a publicly listed company based in San Diego (United States) founded in 2013, and was acquired by Merck in November 2025. Novel anti-infectives for bacterial and fungal infections are developed. Cidara Therapeutics has raised $78.35 million across 8 funding rounds from investors including Merck, Fidelity Investments and NIH. The company has 38 employees. Its chief executive, as recorded, is Jeffrey Stein. Its website cidara.com draws about 16 thousand monthly visits. Cidara Therapeutics offers products and services including Cloudbreak Platform. Its focus areas include Life Sciences, Immunotherapy, Diversified and Infectious Diseases. Its legal entity is CIDARA THERAPEUTICS, INC. Its competitors include BeiGene, Vir Biotechnology and Vaxcyte; 3 of its 3 listed competitors have raised funding.

Company details

Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.

  • Headquarters San Diego, United States
  • Employees 38
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website cidara.com
  • Social LinkedIn X Facebook YouTube
  • Acquired by Merck (Nov 2025)
  • Legal Name Cidara Therapeutics, Inc.
Key Metrics
  • Annual Revenue
    $1.27 M (USD)
    -94.52
    as on Dec 31, 2024
  • Net Profit
    -$168.03 M (USD)
    -632.75
    as on Dec 31, 2024
  • EBITDA
    -$90.99 M (USD)
    -237.71
    as on Dec 31, 2024
  • Total Equity Funding
    $78.35M (USD)

    in 8 rounds

  • Latest Funding Round
    $105M (USD), Post-IPO

    Nov 2024

  • Investors
    Merck

    & 23 more

  • Employee Count
    38
  • Acquired by
    Merck

    (Nov 2025)

Products & Services of Cidara Therapeutics

Cidara Therapeutics offers a comprehensive portfolio of products and services, including Cloudbreak Platform.

Cloudbreak Platform
Immunotherapy Development

Platform creates drug-Fc conjugates for targeted disease treatment.

Apps and channels of Cidara Therapeutics

its YouTube channel Cidara Therapeutics has 46 subscribers and 2 videos.

Cidara Therapeutics
YouTube 46 subscribers 2 videos Science & Technology
Open channel

Videos from Cidara Therapeutics

The most watched videos on Cidara Therapeutics's YouTube channel, Cidara Therapeutics (46 subscribers). Click a video to play it here.

Cloudbreak Antiviral Platform: A Revolutionary Approach to Fight Viral Diseases
3.3K views
Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak® AVCs
644 views

More on Cidara Therapeutics.

Funding Insights of Cidara Therapeutics

Cidara Therapeutics has successfully raised a total of $78.35M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $105 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $78.35M
  • Total Rounds 8
  • Last Round Post-IPO — $105M
  • First Round $36.33M

    (Jun 2014)

  • Investors Count 23

All 8 funding rounds of Cidara Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2024$105MPost-IPO––
Apr 2024$240MPost-IPO––
–
Sep 2019$9.01MPost-IPO––
–
May 2018$1.56MPost-IPO––
–
May 2018$5.5MGrant––
Oct 2017$20.16MPost-IPO––
Feb 2015$42.02MSeries B–CAM Capital, Fidelity Investments
–
Jun 2014$36.33MSeries A–5AM Ventures
Valuation history

24 investors in total: 24 institutional.

Investors in Cidara Therapeutics

Cidara Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Fidelity Investments and NIH.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on tech sectors
venrock.comPalo Alto, United States
tcgcrossover.com
US private equity investments are managed by BVF Partners.
bvflp.comSan Francisco, United States
Venture capital and private equity firm
vivocapital.comPalo Alto, United States
Private equity firm focused on company buyouts
gppfunds.comGreenwich, United States
PE firm investing in Asia and Europe
1993bbbiotech.chSchaffhausen, Switzerland
Investment opportunities in healthcare are managed by Broadfin Capital.
2005broadfin.comMelville, United States
Health-tech companies are targeted for venture capital investments.
1999perceptivelife.comNew York, United States
Venture capital fund backed incubator focused on the healthcare startups
5amventures.comSan Francisco, United States
Healthcare sector private equity investments are managed by the firm.
1991frazierhealthcare.comSeattle, United States
Premium access

Investor details for Cidara Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Cidara Therapeutics

34 people are tracked at Cidara Therapeutics (14 in leadership, 9 in board & advisors, 11 in team); the tracked headcount is 38.

NameRoleGroup
Jeffrey Stein
CEOLeadership
Shane Ward
COO & Chief Legal OfficerLeadership
Donal Gallagher
Associate Director, Clinical Data ManagementLeadership
Laurel Conly
Associate Director, Clinical Project Management And OutsourcingLeadership
Les Tari
Chief Scientific OfficerLeadership
Monica C. Sanford
Associate Director, Clinical OperationsLeadership
Allen borchardt
Senior Director of ChemistryLeadership
Wesley Heaton
Vice President Technical OperationsLeadership
Jodi Schinski
Senior Director, Regulatory AffairsLeadership
Rob Hughes
Senior Director, Pharmaceutical SciencesLeadership
Jennifer Duzak
Director, Purchasing, Facilities & ProgramsLeadership
Karen Mena
Director Clinical OperationsLeadership
Jim Beitel
Chief Business OfficerLeadership
Joaquin Sosa
Senior Director, Clinical Systems & Trial ManagementLeadership
Kieren Marr
Scientific AdvisorBoard & advisors
Frederick G. Hayden
Scientific AdvisorBoard & advisors
Johan A. Maertens
Scientific AdvisorBoard & advisors
Michael G. Ison
Scientific AdvisorBoard & advisors
Ted Schroeder
DirectorBoard & advisors
Dan Burgess
ChairmanBoard & advisors

14 more people are available in the full profile.

Premium access

Complete people profiles for Cidara Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Cidara Therapeutics

Cidara Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CDTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date15 Apr 2015
  • Listed onNASDAQ: CDTX
  • Listed entityCidara Therapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS1717572069
  • Share price$221.38 (+0.03% on the day) · 2026-01-08
  • Market capitalisation$6.96B
  • EPS (diluted, trailing year)$-11.78
  • Volume (last session)2,691,011
  • Analyst consensusNeutral

Financials of Cidara Therapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2024$1.3M-$168.0M-$91.0M
2023$23.3M-$22.9M-$26.9M
2022$64.5M-$33.6M-$33.4M
2021$49.6M-$42.5M-$42.1M
2020$12.1M-$74.9M-$71.6M
Premium access

Detailed financial statements for Cidara Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Cidara Therapeutics

5 dated milestones of Cidara Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cidara Therapeutics is founded.
  2. Funding First funding round of $36.3M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $105.0M.
  5. Exit Acquired by Merck.

Competitors of Cidara Therapeutics

Cidara Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BeiGene, Vir Biotechnology and Vaxcyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
vir.bio2017San Francisco, United States$216M417
Developer of therapeutics for the treatment of infectious diseases
vaxcyte.com2013Foster, United States$347M254
Vaccines for infectious diseases are developed using cell-free protein synthesis.
Premium access

Detailed competitors of Cidara Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Cidara Therapeutics

The website of Cidara Therapeutics (cidara.com) receives about 16.3K visits a month and ranks #1,199,553 among all websites worldwide, #1,507 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    16.3K

    ▼ 27.5% vs previous month

  • Unique visitors
    9.6K

    per month

  • Global rank
    #1,199,553

    among all websites

  • Category rank
    #1,507

    Health · Biotechnology and Pharmaceuticals

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Cidara Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cidara Therapeutics

Premium access

Complete news archive for Cidara Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cidara Therapeutics

Cidara Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Cidara Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Jeffrey Stein is the CEO of Cidara Therapeutics, as recorded in our data.

Cidara Therapeutics is a funded company, having raised a total of $78.35M across 8 funding rounds to date. The company's 1st funding round was a Series A of $36.33M, raised on Jun 2014.

Cidara Therapeutics has 38 employees.

Annual revenue of Cidara Therapeutics is $1.27M as on Dec 31, 2024.

Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.

Cidara Therapeutics's top competitors include BeiGene, Vaxcyte and Vir Biotechnology.

Cidara Therapeutics offers Cloudbreak Platform.

Yes, Cidara Therapeutics is publicly traded on NASDAQ under the ticker symbol CDTX.

Cidara Therapeutics has 24 investors. Key investors include Merck, Fidelity Investments, NIH, RA Capital, and Frazier Healthcare Partners.

Cidara Therapeutics operates through Cidara Therapeutics, Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available